GURU.Markets stock price, segment price, and overall market index valuation
The company's share price OABI
OmniAb is a biotech platform that helps other companies discover and develop new antibodies. Its share price depends on new partnerships and the success of the drugs developed by its partners, from which it receives royalties.
Share prices of companies in the market segment - Pharma tests
OmniAb, Inc. provides its technology platform to other biopharmaceutical companies for the discovery and development of new antibody drug candidates. We've categorized it as "Pharma Tests." The chart below shows how the market values companies providing technology to the pharmaceutical industry.
Broad Market Index - GURU.Markets
OmniAb provides its technology platform to other biopharmaceutical companies for the discovery and development of new antibody drug candidates. It is a component of the GURU.Markets index. The chart below shows the overall market performance. See how this company's stock compares to the overall trend.
Change in the price of a company, segment, and market as a whole per day
OABI - Daily change in the company's share price OABI
Shares of OmniAb, a technology platform for antibody discovery, are exhibiting the volatility inherent in biotech. change_co measures reactions to new partnerships with pharmaceutical companies. This metric forms the basis for analyzing biotech service companies on System.GURU.Markets.
Daily change in the price of a set of shares in a market segment - Pharma tests
OmniAb, Inc. is a biotech platform for antibody discovery. This chart highlights the sector's high volatility. Comparing it to OABI, whose business model relies on royalties from successful drugs, helps assess its long-term potential.
Daily change in the price of a broad market stock, index - GURU.Markets
OmniAb is a biotech company providing a platform for discovering new antibodies. Its business serves as a barometer of activity in the global pharmaceutical industry. The chart below shows general market fluctuations, which can be used to assess OmniAb's stability.
Dynamics of market capitalization of the company, segment and the market as a whole over 12 months
Annual dynamics of the company's market capitalization OABI
OmniAb, Inc.'s year-over-year performance tells the story of its antibody discovery platform. Its market capitalization over the past 12 months has grown not so much from its own developments as from the success of its partners—dozens of pharmaceutical companies that use its genetically modified mice to create new drugs and pay it royalties.
Annual dynamics of market capitalization of the market segment - Pharma tests
OmniAb, Inc. provides a technology platform for discovering new antibodies to pharmaceutical companies. Its business model is based on royalties from future drug sales. The chart below shows how the market views the potential of its platform and the long-term prospects of its partnerships.
Annual dynamics of market capitalization of broad market stocks, index - GURU.Markets
OmniAb, with its antibody discovery platform, is a gold mine for biotech. Demand for its services is not dependent on the economy, but is driven by pharmaceutical companies' R&D budgets. The company's stock price reflects the long-term trend toward faster and cheaper drug development, making it a defensive technology bet.
Dynamics of market capitalization of the company, segment and the market as a whole for the month
Monthly dynamics of the company's market capitalization OABI
OmniAb's value as an antibody company will depend on its R&D cycles. Monthly fluctuations on the chart will reflect not its own sales, but rather news about the success of its partners using its platform to create new drugs and the signing of new licensing agreements.
Monthly dynamics of market capitalization of the market segment - Pharma tests
OmniAb is a biotech platform that helps pharmaceutical companies discover and develop new antibodies for drug development. It is a technology provider for the entire industry. The chart below shows the overall dynamics of the biotech testing and platform sector.
Monthly dynamics of market capitalization of broad market stocks, index - GURU.Markets
OmniAb, Inc. provides its technology platform to other pharmaceutical companies for the discovery of new antibodies. Its revenue comes from licensing fees and royalties. Its stock performance reflects the success of its partners in drug development, creating a unique and diversified profile in the biotech sector.
Dynamics of market capitalization of the company, segment and the market as a whole for the week
Weekly dynamics of the company's market capitalization OABI
Shares of OmniAb, a technology platform for discovering new antibodies, reflect activity in the biopharmaceutical industry. Weekly price movements depend on news of licensing agreements with pharmaceutical companies and progress in developing partner drugs. The chart below shows how short-term events in the biotech sector influence the company's valuation.
Weekly dynamics of market capitalization of the market segment - Pharma tests
Is OmniAb outperforming its biotech peers? This chart compares the weekly stock performance of this antibody discovery platform with the industry average. This allows us to assess whether its business model (licensing) is less volatile than companies conducting their own clinical trials, or whether it follows general trends.
Weekly dynamics of market capitalization of stocks of the broad market, index - GURU.Markets
OmniAb provides a technology platform for pharmaceutical companies to discover new antibodies. Its business is the "shovels and picks" of the biotech industry. This chart compares its weekly performance to the market to assess how its results are influenced by the overall level of funding and activity in the biotech industry.
Market capitalization of the company, segment and market as a whole
OABI - Market capitalization of the company OABI
OmniAb, Inc.'s valuation on the chart is a bet on its technology platform for discovering human antibodies, which could form the basis for new drugs. The company's market cap depends on the success of its pharmaceutical partners who use its technology. The dynamics show how investors value this royalty-based business model.
OABI - Share of the company's market capitalization OABI within the market segment - Pharma tests
OmniAb, Inc. maintains its market share by providing its technology platform for discovering new antibodies to other pharmaceutical companies. Its market capitalization reflects its business model, which relies on licensing fees and royalties.
Market capitalization of the market segment - Pharma tests
Here's a chart showing the total market capitalization of biotech companies that don't develop drugs themselves, but rather provide the technology for their discovery. OmniAb is the leader in this niche. The graph shows how the market values these platforms, which receive royalties from the successes of the entire pharmaceutical industry.
Market capitalization of all companies included in a broad market index - GURU.Markets
Here's a visualization of the market value of drug discovery technology. OmniAb's market capitalization is the valuation of its therapeutic antibody discovery platform. The graph shows the importance of this "idea factory" that equips the entire pharmaceutical industry with tools to fight diseases.
Book value capitalization of the company, segment and market as a whole
OABI - Book value capitalization of the company OABI
OmniAb, Inc.'s book value represents its scientific capital. The chart below reflects the valuation of its unique technology platform for discovering and developing human antibodies. The pipeline's growth reflects research successes and partnerships with pharmaceutical companies, which are the primary embodiment of the value of its technology.
OABI - Share of the company's book capitalization OABI within the market segment - Pharma tests
OmniAb's tangible assets are not factories, but cutting-edge laboratories and a technological platform for discovering new antibodies, which are then licensed to pharmaceutical companies. The chart shows its share of this unique scientific infrastructure, which serves as a "factory" for future drugs.
Market segment balance sheet capitalization - Pharma tests
Below you can see the overall book value of the biotech sector. Compared to this, OmniAb, as a platform for discovering new antibodies, looks "light." It doesn't create drugs itself, but rather provides the technology to others. Its value lies in its intellectual property, not its manufacturing facilities.
Book value of all companies included in the broad market index - GURU.Markets
OmniAb is not a pharmaceutical company, but a technology company that discovers and licenses antibodies to other pharmaceutical companies. Its assets are not drugs, but rather a biological platform (genetically modified animals) and patents. Their balance sheet represents the value of a "factory for inventing keys" to disease treatments.
The ratio of market capitalization to book capitalization of a company, segment, and the market as a whole
Market capitalization to book capitalization ratio - OABI
OmniAb's balance sheet is its scientific platform. Its market capitalization is a measure of its ability to "invent" antibodies for the entire pharmaceutical industry. The MvsBCap_Co chart shows the premium investors pay for a "drug idea factory," not for the drugs themselves.
Market to book capitalization ratio in a market segment - Pharma tests
OmniAb provides biotech companies with its platform for discovering antibodies that could form the basis of new drugs. Its value lies in its technology. The chart shows how the market values its licensing and royalty model, which allows it to participate in the success of many pharmaceutical companies.
Market to book capitalization ratio for the market as a whole
OmniAb provides biotech and pharmaceutical companies with its platform for discovering and developing new therapeutic antibodies. The company's value lies in its technology. This chart illustrates why companies providing key technology platforms to the pharmaceutical industry can command a premium.
Debts of the company, segment and market as a whole
OABI - Company debts OABI
OmniAb, a company providing a technology platform for discovering new antibodies, uses debt to finance R&D. This chart shows how the company invests in developing its technologies, which are then licensed to dozens of pharmaceutical partners. Debt here represents an investment in the platform, which accelerates the development of new drugs.
Market segment debts - Pharma tests
OmniAb provides its technology platform to pharmaceutical companies for the discovery and development of new antibody drugs. Its business model is based on partnerships and royalty payments. This chart shows how the biotech platform, which does not conduct its own clinical trials, funds its cutting-edge research and development.
Market debt in general
Debt to book value of the company, segment and market as a whole
The company's debt to book capitalization ratio OABI
OmniAb provides its technology platform to other pharmaceutical companies for antibody discovery and development. This chart shows how the company finances its research and development. For a technology platform with a royalty model, a low debt load can be a sign of financial health, as revenue can be irregular and dependent on the success of its partners.
Market segment debt to market segment book capitalization - Pharma tests
OmniAb provides biotech companies with a platform for discovering new antibodies for therapeutic use. Its business model is based on technology licensing and royalties. The chart shows how conservatively the company manages its debt compared to the overall market capitalization of the biotech sector.
Debt to book value of all companies in the market
OmniAb (OABI) provides a technology platform for the discovery and development of human antibodies for pharmaceutical companies. This is a service model in biotech. This chart shows the debt burden of the entire economy. It's interesting to analyze how a company with this business model manages its finances compared to biotech companies developing their own drugs.
P/E of the company, segment and market as a whole
P/E - OABI
This metric is a measure of R&D success for OmniAb, Inc., a company that provides its technology platform for discovering new antibodies to other pharmaceutical companies. The P/E ratio is based on upfront fees, royalties, and milestone payments from its partners. The valuation increases as drugs developed using its platform advance through the clinical trials.
P/E of the market segment - Pharma tests
This is the average P/E for biotech companies. For OmniAb, which licenses its antibody discovery technology, this is an important benchmark. It helps understand how investors value its royalty-based business model compared to companies that develop and market their own drugs.
P/E of the market as a whole
OmniAb provides biotech and pharmaceutical companies with its platform for the discovery and development of human antibodies as drugs. OmniAb's technologies are used by partners to create new therapeutics. This chart, reflecting overall sentiment, helps understand how investors value companies providing technology to the pharmaceutical industry.
Future P/E of the company, segment and market as a whole
Future (projected) P/E of the company OABI
OmniAb provides its technology platform to pharmaceutical companies for the discovery and development of new therapeutic antibodies. This graph reflects expectations for future drug development. Estimates are based on the number of partnerships, the success of drugs created using its technology, and royalties from future sales, creating a diversified revenue stream.
%20P%2FE%20OABI&width=1500&height=450&colorIndex=35&filename=GURU_Markets_-_Chart-of-the-companys-future-projected-PE-OABI&v=1772513217654 "Chart of the company's future (projected) P/E OABI")
Future (projected) P/E of the market segment - Pharma tests
OmniAb provides a technology platform for the discovery and development of human antibodies for therapeutic use. This chart reflects the company's long-term profitability expectations. It demonstrates the market's confidence that their technology will be in demand by pharmaceutical companies for the development of new drugs, providing OmniAb with a stream of royalties.
%20P%2FE%20graph%20of%20the%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=36&filename=GURU_Markets_-_Future-projected-PE-graph-of-the-market-segment-Pharma-tests&v=1772513217658 "Future (projected) P/E graph of the market segment - Pharma tests")
Future (projected) P/E of the market as a whole
OmniAb provides its technology platform to other pharmaceutical companies for the discovery and development of new antibodies. Its business model is based on royalties and licensing fees. This market expectations chart is an indicator of R&D activity. Growing optimism in the pharmaceutical sector means more projects and, consequently, more potential partners for OmniAb.
%20P%2FE%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=37&filename=GURU_Markets_-_Chart-of-the-future-projected-PE-of-the-market-as-a-whole&v=1772513217669 "Chart of the future (projected) P/E of the market as a whole")
Profit of the company, segment and market as a whole
Company profit OABI
OmniAb provides its technology platform to pharmaceutical companies for the discovery and development of new antibody drug candidates. The company does not sell drugs, but receives payments for the use of its technology, as well as royalties on future sales. Its financial performance depends on the success of its partners.
Profit of companies in the market segment - Pharma tests
OmniAb provides biotech companies with a platform for discovering new antibodies that could become drugs. It receives payments and royalties without bearing the risks of clinical trials. This chart illustrates how technology platforms in biotech are creating a diversified and less risky business model, influencing the overall profitability of the R&D sector.
Overall market profit
OmniAb is a biotech platform that helps other companies discover new antibodies for drug development. OmniAb receives payments for the use of its technology and royalties from future sales. Its business model benefits from overall R&D activity in the pharmaceutical industry, which can be more stable than the overall economy.
Future (predicted) profit of the company, segment and market as a whole
Future (projected) profit of the company OABI
OmniAb provides its technology platform to other companies for the discovery and development of new antibody drugs. This chart shows revenue expectations, which depend on the success of its partners. The company's revenue consists of license fees and royalties from sales of drugs discovered using its technology.
%20profit%20of%20the%20company%20OABI&width=1500&height=450&colorIndex=41&filename=GURU_Markets_-_Graph-of-future-projected-profit-of-the-company-OABI&v=1772513217695 "Graph of future (projected) profit of the company OABI")
Future (predicted) profit of companies in the market segment - Pharma tests
OmniAb provides a biotech platform that helps pharmaceutical companies discover new antibodies for drug development. This chart shows the revenue forecast for the pharmaceutical testing and services sector. It reflects expectations for R&D spending in the pharmaceutical industry. This trend is the main driver of demand for OmniAb's technology platform.
%20profits%20of%20companies%20in%20a%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=42&filename=GURU_Markets_-_Graph-of-future-predicted-profits-of-companies-in-a-market-segment-Pharma-tests&v=1772513217699 "Graph of future (predicted) profits of companies in a market segment - Pharma tests")
Future (predicted) profit of the market as a whole
OmniAb provides its technology platform to other companies for the discovery and development of new antibody drugs. Its revenue comes from royalties and payments from partners. Its success depends on R&D activity in the pharmaceutical industry. The growth forecasts in this chart indicate that pharmaceutical companies will have the funds to invest in the development of new drugs.
%20profits%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=43&filename=GURU_Markets_-_Chart-of-future-predicted-profits-of-the-market-as-a-whole&v=1772513217709 "Chart of future (predicted) profits of the market as a whole")
P/S of the company, segment and market as a whole
P/S - OABI
OmniAb is a biotech platform that helps pharmaceutical companies discover new antibodies for drug development. It licenses its technology and receives payments and royalties. This chart shows how investors view its business model, which allows it to profit from the successes of the entire pharmaceutical industry.
P/S market segment - Pharma tests
OmniAb is a biotech platform that helps pharmaceutical companies discover and develop new therapeutic antibodies. OmniAb doesn't create drugs itself, but licenses its technology to other companies, receiving royalties. This chart shows the average valuation in the sector, helping to understand how the market values this unique technology-based business model.
P/S of the market as a whole
OmniAb is a biotech platform that helps pharmaceutical companies discover and develop new antibodies for drug development. The company doesn't develop drugs itself, but rather provides its technology to partners for royalties. This chart shows the premium the market is willing to pay for a scalable, high-margin pharma technology platform.
Future P/S of the company, segment and market as a whole
Future (projected) P/S of the company OABI
OmniAb provides a technology platform for pharmaceutical companies to discover new antibodies. Future revenues depend on licensing fees and royalties from future sales of drugs developed using its technology. This graph reflects investors' confidence in the value of its platform and the future success of its partners.
%20P%2FS%20OABI&width=1500&height=450&colorIndex=47&filename=GURU_Markets_-_The-graph-of-the-companys-future-projected-PS-OABI&v=1772513217744 "The graph of the company's future (projected) P/S OABI")
Future (projected) P/S of the market segment - Pharma tests
OmniAb provides a technology platform for the pharmaceutical industry to discover therapeutic antibodies. This chart compares market expectations for its future revenue with other pharmaceutical testing companies. This valuation reflects investor confidence in its cutting-edge technology and its partnership- and royalty-based business model.
%20P%2FS%20market%20segment%20graph%20-%20Pharma%20tests&width=1500&height=450&colorIndex=48&filename=GURU_Markets_-_Future-projected-PS-market-segment-graph-Pharma-tests&v=1772513217750 "Future (projected) P/S market segment graph - Pharma tests")
Future (projected) P/S of the market as a whole
OmniAb provides biotech companies with a platform for discovering new antibodies that could become drugs. It is a technology provider for R&D. Market optimism, as seen in this chart, indicates increased investment in pharmaceutical research. This directly increases demand for the OmniAb platform from companies seeking new drugs.
%20P%2FS%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=49&filename=GURU_Markets_-_Chart-of-the-future-projected-PS-of-the-market-as-a-whole&v=1772513217754 "Chart of the future (projected) P/S of the market as a whole")
Sales of the company, segment and market as a whole
Company sales OABI
OmniAb provides biotech companies with its platform for discovering new antibodies that could form the basis of future drugs. The company's revenue comes from licensing fees, as well as milestone payments and royalties from partners using its technology. The chart shows the financial impact of these partnerships.
Sales of companies in the market segment - Pharma tests
OmniAb is a biotech platform that helps pharmaceutical companies discover new antibodies for drug development. The company does not develop drugs itself, but licenses its technology to partners, receiving upfront fees, royalties, and other payments. This chart shows activity in antibody drug development, where OmniAb is a key technology partner.
Overall market sales
OmniAb provides its technology platform to pharmaceutical companies to discover new antibody drug candidates. Its revenue depends on the success of its partners and its R&D activity. This schedule, reflecting the state of the economy, influences R&D budgets in the pharmaceutical industry, which is key for OmniAb.
Future sales volume of the company, segment and market as a whole
Future (projected) sales of the company OABI
OmniAb is a biotech company that doesn't develop drugs itself, but rather provides its technology platform for discovering and developing antibodies to other pharmaceutical companies. It receives payments for using the platform and royalties. This chart reflects analysts' expectations for the number of partnerships and the success of drugs created using OmniAb's technology.
%20sales%20of%20the%20company%20OABI&width=1500&height=450&colorIndex=53&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-the-company-OABI&v=1772513217774 "Schedule of future (projected) sales of the company OABI")
Future (projected) sales of companies in the market segment - Pharma tests
OmniAb provides biotech companies with a platform for discovering and developing new antibodies for therapeutic purposes. This chart provides a forecast for the pharmaceutical services sector. It allows us to assess how the company monetizes its cutting-edge technology through partnerships and licensing agreements, benefiting from the success of the entire pharmaceutical industry.
%20sales%20of%20companies%20in%20the%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=54&filename=GURU_Markets_-_Schedule-of-future-projected-sales-of-companies-in-the-market-segment-Pharma-tests&v=1772513217779 "Schedule of future (projected) sales of companies in the market segment - Pharma tests")
Future (projected) sales of the market as a whole
OmniAb, Inc. provides a platform for the discovery and development of human antibodies for pharmaceutical companies. This chart, reflecting R&D activity, is a direct indicator for OmniAb. Growing drug development budgets are incentivizing pharmaceutical companies to utilize advanced platforms to accelerate the process, driving OmniAb's business.
%20sales%20of%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=55&filename=GURU_Markets_-_Schedule-of-future-predicted-sales-of-the-market-as-a-whole&v=1772513217787 "Schedule of future (predicted) sales of the market as a whole")
Marginality of the company, segment and market as a whole
Company marginality OABI
OmniAb, Inc. provides its technology platform to other pharmaceutical companies for the discovery and development of new antibody drugs. The business model is based on licensing fees, milestone payments, and royalties. This chart illustrates how the company is transforming its technological capabilities into a diversified and potentially highly profitable revenue stream.
Market segment marginality - Pharma tests
OmniAb, Inc. provides a biotechnology platform that helps pharmaceutical companies discover new antibodies for drug development. They don't develop the drugs themselves, but license their technology. This royalty- and partnership-based model has the potential for high profitability, as this graph should reflect in the long term.
Market marginality as a whole
OmniAb provides its technology platform to pharmaceutical companies for the discovery and development of new antibodies. Contrary to the general picture of profitability, their business is based on royalties and license fees. They are a "shovel supplier" to the pharmaceutical industry. Their profitability depends on the R&D success of their partners, not the state of the economy.
Employees in the company, segment and market as a whole
Number of employees in the company OABI
OmniAb is a biotech company that provides its platform to pharmaceutical companies for the discovery of new antibodies. This graph shows the team's scientists. The company's model is based on licensing fees and royalties, so staff growth reflects investment in the technology rather than in-house clinical development.
Share of the company's employees OABI within the market segment - Pharma tests
OmniAb provides biotech companies with its platform for discovering new antibodies that could form the basis of future drugs. This chart shows its share of the R&D services sector. It reflects its team of scientists, who help dozens of partners accelerate the development of innovative therapeutics without having to develop them themselves.
Number of employees in the market segment - Pharma tests
OmniAb, Inc. provides a platform for the discovery and development of human antibodies for pharmaceutical companies. This chart shows the growth of employment in the biotech services sector. The increase in scientists reflects the high demand for drug discovery technologies, as OmniAb serves as a technology partner for the entire pharmaceutical industry.
Number of employees in the market as a whole
OmniAb, Inc. provides its technology platform to other pharmaceutical companies for the discovery and development of new antibodies for therapeutic purposes. This is the "picks and shovels" business model of biotech. This graph illustrates the overall employment, and companies like OmniAb are key partners for the entire industry, accelerating research and indirectly driving growth in the sector.
Market capitalization per employee (in thousands of dollars) of the company, segment, and market as a whole
Market capitalization per employee (in thousands of dollars) of the company OABI (OABI)
OmniAb, Inc. provides its technology platform to other companies to discover new antibody drugs. This is a business model based on intellectual property. This chart demonstrates a very high return on investment per employee. Their platform, developed by a team of scientists, is used by many pharmaceutical companies, generating royalties and payments with minimal additional costs.
%20of%20the%20company%20OABI%20(OABI)&width=1500&height=450&colorIndex=63&filename=GURU_Markets_-_Chart-of-market-capitalization-per-employee-in-thousands-of-dollars-of-the-company-OABI-OABI&v=1772513217885 "Chart of market capitalization per employee (in thousands of dollars) of the company OABI (OABI)")
Market capitalization per employee (in thousands of dollars) in the market segment - Pharma tests
ATN International owns and operates telecommunications companies in North America and the Caribbean. In the telecoms sector, this metric reflects the efficiency of infrastructure and subscriber base management. The chart allows one to assess how successfully ATN creates value per employee while operating in small and often remote markets.
%20by%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=64&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-by-market-segment-Pharma-tests&v=1772513217911 "Market capitalization per employee (in thousands of dollars) by market segment - Pharma tests")
Market capitalization per employee (in thousands of dollars) for the overall market
OmniAb provides biotech companies with its platform for discovering new antibodies that could become the basis for drugs. This is the "technology as a service" model in pharmaceuticals. This graph shows a high market value per employee, reflecting the value of their platform, which accelerates R&D for the entire industry.
%20for%20the%20overall%20market&width=1500&height=450&colorIndex=65&filename=GURU_Markets_-_Market-capitalization-per-employee-in-thousands-of-dollars-for-the-overall-market&v=1772513217926 "Market capitalization per employee (in thousands of dollars) for the overall market")
Profit per employee (in thousands of dollars) for the company, segment, and market as a whole
Profit per employee (in thousands of dollars) of the company OABI (OABI)
OmniAb (OABI) is a biotech platform. They don't develop drugs themselves, but rather provide their technology (transgenic mice) to other pharmaceutical companies to discover new antibodies. This chart shows how effective their "licensing" model is. It measures how much profit (from royalties) each of their scientists generates.
%20Chart%20OABI%20(OABI)&width=1500&height=450&colorIndex=66&filename=GURU_Markets_-_Company-Profit-Per-Employee-in-thousands-of-dollars-Chart-OABI-OABI&v=1772513217945 "Company Profit Per Employee (in thousands of dollars) Chart OABI (OABI)")
Profit per employee (in thousands of dollars) in the market segment - Pharma tests
OmniAb doesn't develop drugs itself, but rather provides its platform to other pharmaceutical companies for the discovery of new antibodies. Their business is "R&D as a service" and royalty payments. This chart demonstrates the benchmark for personnel efficiency in biotech. It is important for assessing how successfully OmniAb is monetizing its unique platform.
%20in%20the%20market%20segment%20-%20Pharma%20tests&width=1500&height=450&colorIndex=67&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-in-the-market-segment-Pharma-tests&v=1772513217965 "Chart of profit per employee (in thousands of dollars) in the market segment - Pharma tests")
Profit per employee (in thousands of dollars) for the market as a whole
OmniAb is a technology platform. They don't create drugs themselves, but rather "discover" antibodies for other pharmaceutical companies using their platform (for example, genetically modified mice) and receive royalties for doing so. It's a highly leveraged business model. This graph shows how efficiently their platform (IP) generates revenue with minimal staff involvement.
%20for%20the%20market%20as%20a%20whole&width=1500&height=450&colorIndex=68&filename=GURU_Markets_-_Chart-of-profit-per-employee-in-thousands-of-dollars-for-the-market-as-a-whole&v=1772513217975 "Chart of profit per employee (in thousands of dollars) for the market as a whole")
Sales to employees of the company, segment and market as a whole
Sales per company employee OABI (OABI)
OmniAb is a biotech platform that helps pharmaceutical companies discover new antibodies for drug development. This chart illustrates its business model. Revenue per employee is generated from licensing fees and royalties from partners using its technology. This allows the platform to be monetized with a small staff.
&width=1500&height=450&colorIndex=69&filename=GURU_Markets_-_Sales-chart-per-company-employee-OABI-OABI&v=1772513217981 "Sales chart per company employee OABI (OABI)")
Sales per employee in the market segment - Pharma tests
OmniAb (OABI) is a biotech company that provides pharmaceutical companies with its technology platform (including transgenic animals) for the discovery of new antibodies. This chart shows the revenue (from licenses and royalties) generated by each employee (scientist). It's an indicator of the value of their "discovery-as-a-service" R&D platform.
Sales per employee for the market as a whole
OmniAb, Inc. (OABI) is a technology platform. They don't create drugs themselves, but provide biotech companies with access to their systems to discover new antibodies. This is a royalty-based model. This graph shows how their small staff of scientists generates revenue (in the form of royalties) from the success of their numerous partners, demonstrating the high value of their IP.
Short shares by company, segment and market as a whole
Shares shorted by company OABI (OABI)
OmniAb is a biotech company that doesn't develop its own drugs, but rather provides its platform (based on transgenic animals) to other pharmaceutical companies for the discovery of new antibodies. This chart shows bearish bets. The short position could be due to the fact that its revenue depends on the success of its partners' R&D, which is an unpredictable factor.
&width=1500&height=450&colorIndex=72&filename=GURU_Markets_-_Short-Shares-Chart-for-the-Company-OABI-OABI&v=1772513218000 "Short Shares Chart for the Company OABI (OABI)")
Shares shorted by market segment - Pharma tests
OmniAb (OABI) is a biotech platform that helps pharmaceutical companies "discover" new antibodies for drug development. This chart shows the odds against the entire biotech sector. The rising odds against the industry reflect concerns that biotech companies will cut R&D budgets, which will directly reduce demand for OmniAb's platform services.
Shares shorted by the overall market
OmniAb (OABI) provides a technology platform (antibodies) for other pharmaceutical companies to develop drugs. It's a B2B biotech company. When this chart shows rising fear, investors fear that OABI's biotech clients will cut R&D budgets, which will reduce demand for its platform.
RSI 14 indicator for a company, segment, and market as a whole
The company's RSI 14 indicator OABI (OABI)
OmniAb provides a platform for antibody discovery for pharmaceutical companies, receiving royalties and fees. Its business depends on the success of its R&D partners. A chart above 70 may reflect new partnerships or drug successes. A level below 30 indicates concerns about a slowdown in R&D or failures among partners.
&width=1500&height=450&colorIndex=75&filename=GURU_Markets_-_RSI-14-indicator-chart-for-the-companys-stock-OABI-OABI&v=1772513218029 "RSI 14 indicator chart for the company's stock OABI (OABI)")
RSI 14 Market Segment - Pharma tests
OmniAb is a technology platform. The company doesn't sell drugs, but uses its technologies (including AI) to "discover" new antibodies, which it then licenses to other pharmaceutical companies. This is the R&D "infrastructure." This chart measures the collective momentum of the biotech platform sector. It shows whether the entire biotech sector is overheated or whether investors value OmniAb's model.
RSI 14 for the overall market
OmniAb (OABI) is a biotech platform. This chart is an indicator of R&D health. In the euphoria of the moment, biotechs (OABI clients) are generously funded and launch hundreds of clinical trials using its platform. In the panic, R&D funding freezes, the number of trials drops, and demand for OABI's services declines.
Analyst consensus forecast for the company's share price, the segment, and the market as a whole
Analyst consensus stock price forecast OABI (OABI)
OmniAb is a biotech platform (spinned out of Ligand) that uses genetically modified animals to discover new human antibodies for pharmaceutical companies. This chart shows the average analyst forecast. Their targets are based on the number of new partnerships and potential royalties from future drugs.
&width=1500&height=450&colorIndex=78&filename=GURU_Markets_-_A-chart-showing-analyst-consensus-forecasts-for-the-expected-stock-price.-OABI-OABI&v=1772513218050 "A chart showing analyst consensus forecasts for the expected stock price. OABI (OABI)")
The difference between the consensus estimate and the actual stock price OABI (OABI)
OmniAb (OABI) is a biotech platform (a spin-off of Ligand) that uses transgenic animals (with human immunity) to discover new antibodies for pharmaceutical companies. This chart shows the valuation of their technology. It measures the gap between the price and the consensus target, reflecting the potential analysts see in their R&D platform.
&width=1500&height=450&colorIndex=79&filename=GURU_Markets_-_A-chart-showing-the-difference-between-the-consensus-forecast-and-the-actual-stock-price.-OABI-OABI&v=1772513218054 "A chart showing the difference between the consensus forecast and the actual stock price. OABI (OABI)")
Analyst consensus forecast for stock prices by market segment - Pharma tests
OmniAb (OABI) is an "antibody library." The company uses its "genetically modified" rodents to discover the best antibodies, which it licenses to pharmaceutical companies for drug development. This chart shows general expectations for the pharma testing sector. It reflects whether experts believe in outsourcing R&D at an early stage.
Analysts' consensus forecast for the overall market share price
OmniAb is a biotech company that doesn't develop drugs itself, but licenses its platform (smart mouse technology) to other pharmaceutical companies to discover new antibodies. This chart shows the overall "risk appetite." For OmniAb, whose income comes from royalties and payments from partners, the overall optimism is important, as it reflects the high level of R&D activity in the pharmaceutical industry.
AKIMA index of the company, segment and market as a whole
AKiMA Company Index OABI
OmniAb (OABI) is the goose that lays the golden eggs. They don't make drugs. Their platform is biological intelligence: they provide pharmaceutical companies (their partners) with genetically modified animals that produce human antibodies for R&D. This chart is an assessment of their platform. It reflects their ability to secure new partnerships and their future royalties from their clients' successful drugs.
AKIMA Market Segment Index - Pharma tests
OmniAb provides biotech companies with a platform (based on transgenic animals) for discovering new antibodies that are later developed into drugs. This is a business-to-business (B2B) model in science. This chart shows the average index for the pharmaceutical testing sector. It allows one to assess how OmniAb's technological platform compares in terms of effectiveness against the industry average.
The AKIM Index for the overall market
OmniAb is a technology platform that provides partners with access to a variety of antibodies for drug development. It operates on a royalty-free model. This chart, reflecting the market average, is a backdrop. It helps assess how OABI, the driving force behind discovery for the entire industry, compares to overall macroeconomic trends in biotech.
